Moreover, as adaptive ICIs such as αPD-1/ αPD–L1 did not improve response rates in these patients [2, 3], the combination with innate CD47 blockade using LicMAbs might synergize analogously with other cancer entities [45, 46]. The gene discussed is CD47; the disease is cancer.